Abivax S.a. (ABVX)

$10.27

-0.05

(-0.48%)

Market is closed - opens 7 PM, 04 Nov 2024

Performance

  • $10.21
    $10.38
    $10.27
    downward going graph

    0.58%

    Downside

    Day's Volatility :1.59%

    Upside

    1.01%

    downward going graph
  • $8.75
    $17.02
    $10.27
    downward going graph

    14.8%

    Downside

    52 Weeks Volatility :48.59%

    Upside

    39.66%

    downward going graph

Returns

PeriodAbivax S.a.Index (Russel 2000)
3 Months
-7.06%
0.0%
6 Months
-29.37%
0.0%
1 Year
1.68%
0.0%
3 Years
23.73%
-26.4%

Highlights

Market Capitalization
673.7M
Book Value
$2.01
Earnings Per Share (EPS)
-3.71
Wall Street Target Price
36.09
Profit Margin
0.0%
Operating Margin TTM
-1178.84%
Return On Assets TTM
-46.69%
Return On Equity TTM
-171.46%
Revenue TTM
9.0M
Revenue Per Share TTM
0.16
Quarterly Revenue Growth YOY
201.9%
Gross Profit TTM
0.0
EBITDA
-169.9M
Diluted Eps TTM
-3.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-3.05
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Abivax S.a.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 251.41%

Current $10.27
Target $36.09

Technicals Summary

Sell

Neutral

Buy

Abivax S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abivax S.a.
Abivax S.a.
-0.19%
-29.37%
1.68%
23.73%
23.73%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-16.85%
-11.85%
3.27%
29.37%
171.22%
Biontech Se
Biontech Se
-6.94%
20.23%
16.39%
-62.26%
487.66%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
1.63%
79.81%
63.67%
58.45%
198.57%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.87%
17.46%
25.23%
149.18%
136.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abivax S.a.
Abivax S.a.
NA
NA
NA
0.0
-1.71
-0.47
NA
2.01
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.75
20.75
1.18
44.77
0.17
0.08
NA
242.47
Biontech Se
Biontech Se
160.8
NA
0.04
-2.76
-0.03
-0.02
NA
80.22
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.39
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abivax S.a.
Abivax S.a.
Buy
$673.7M
23.73%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$101.7B
171.22%
20.75
32.04%
Biontech Se
Biontech Se
Buy
$27.1B
487.66%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
198.57%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
136.25%
32.84
-4.74%

Insights on Abivax S.a.

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.7% return, outperforming this stock by 62.0%

Company Information

Organization
Abivax S.a.
Employees
62
CEO
Mr. Marc M. P. de Garidel M.B.A.
Industry
Miscellaneous

FAQs